South Korea
About Dong-A Socio Holdings Co., Ltd.
Dong-A Socio Holdings Co., Ltd., along with its subsidiaries, operates as a key player in South Korea's pharmaceutical and healthcare industry. The company is structured into multiple segments to streamline its diverse operations.
Business Segments
- Holding Company – Oversees corporate strategy and subsidiary management.
- Over-the-Counter Drugs and Quai-Drugs – Provides accessible healthcare solutions.
- Biosimilars and Consignment Medicines – Focuses on developing biosimilar treatments.
- Logistics – Manages supply chain and distribution.
- Packaging Solutions – Offers packaging for pharmaceuticals and beverages.
- Others – Includes IT, construction, and real estate services.
Key Products & Developments
- DA-8010 – Phase 3 clinical trial for overactive bladder treatment.
- DMB-3115 – Biosimilar of Stelara in Phase 3 trials.
- DA-1241 – Phase 2 trial for non-alcoholic steatohepatitis.
- DA-1726 – Phase 1 obesity treatment.
- STP0404 – AIDS treatment under development.
Additional Offerings
- Medical devices and healthcare solutions.
- Functional sports drinks (POCARI SWEAT brand).
- Contract manufacturing for biosimilars and oligonucleotide therapeutics.
- Logistics, packaging, and fulfillment services.
- Beverages, including mineral water and carbonated drinks.
- Real estate, consulting, and construction services.
Founded: 1932 | Headquarters: Seoul, South Korea
